<DOC>
	<DOCNO>NCT02049606</DOCNO>
	<brief_summary>This randomize , double-blind study compare efficacy safety LAYLA tablet CENATONE tablet treatment osteoarthritis knee .</brief_summary>
	<brief_title>To Compare Efficacy Safety LAYLA Osteoarthritis Patients Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Patients ≥40 ≤80 year age Radiographic evidence grade 1,2 3 osteoarthritis base Kellgren &amp; Lawrence radiographic entry criterion Stable osteoarthritis 3 month Score 100mm Pain VAS ≤ 80mm screen Score 100mm Pain VAS ≥ 40mm baseline Written consent form voluntarily Disease spine Lower limb joint could affect fo evaluate efficacy History surgery arthroscopy study joint within 6 month Trauma study joint within 12 month Medication constantly ( 1 week ) corticosteroid oral within 3 month Diagnosed psychical disorder , take medication Medication intraarticular injection within 3 month Uncontrollable Hypertension patient screen test History upper gastrointestinal ulceration within 6 month , History upper gastrointestinal bleeding within 12 month History low gastrointestinal bleeding within 12 month History coronary artery bypass , systemic lupus erythematosus mixed connective tissue disease Serum creatinine , ALT , AST , total bilirubin ULN X 2.0 screen test History hypersensitivity LAYLA , CENATONE NSAIDs Participation another clinical trial within 4 week Medication constantly ( 1 week ) narcotic analgesic within 3 month Not consent use effectual contraception method trial Pregnant lactate woman History malignant tumor within 5 year Investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>LAYLA</keyword>
	<keyword>Non-inferiority</keyword>
	<keyword>100mm pain VAS</keyword>
</DOC>